Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015		Mar. 31, 2014
Revenue:
Product revenue	$ 329,520	$ 229,950		$ 183,280
Funded research and development	23	361		363
Total Revenue	329,543	230,311		183,643
Costs and expenses:
Cost of product revenue	50,419	39,945		37,322
Research and development	49,759	35,973		30,707
Selling, general and administrative	164,261	125,727		107,251
Costs and Expenses, Total	264,439	201,645		175,280
Income from operations	65,104	28,666		8,363
Other income:
Investment income, net	395	196		118
Other income (expense), net	339	(97)		49
Nonoperating Income (Expense), Total	734	99		167
Income before income taxes	65,838	28,765		8,530
Income tax provision (benefit)	27,691	(84,923)	[1]	1,179
Net income	$ 38,147	$ 113,688		$ 7,351
Basic net income per share	$ 0.90	$ 2.80		$ 0.19
Basic weighted average shares outstanding	42,204	40,632		39,334
Diluted net income per share	$ 0.85	$ 2.65		$ 0.18
Diluted weighted average shares outstanding	44,895	42,858		41,606

[1] Income tax benefit for the quarter and year ended March 31, 2015 were impacted by the release of the $101.5 million valuation allowance on certain deferred tax assets.